Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 106, Issue 4

Recent advances in the prevention and treatment of respiratory syncytial virus disease Open Access

Abstract

Respiratory syncytial virus (RSV) is associated with considerable healthcare burden; as such, prevention and treatment of RSV have long been considered a priority. Historic failures in RSV vaccine development had slowed the research field. However, the discovery of the conformational change in the RSV fusion protein (F) has led to considerable advancements in the field. The RSV pharmaceutical landscape has drastically changed in recent years with successful trials of both vaccines and second-generation mAbs leading to licensing and roll-out of these agents in several countries. RSV preventative and therapeutic measures will likely have a significant impact on RSV-related morbidity and mortality. However, there are still gaps in the protection that these immunizations offer that should be addressed. Many unanswered questions about RSV infection dynamics and subsequent disease should be a focus of ongoing research. This review discusses the currently licensed RSV pharmaceuticals and others that have recently progressed to clinical trials.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antivirals , mAbs , respiratory syncytial virus and vaccines
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.002095
2025-04-09
2026-03-08

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jgv/106/4/jgv002095.html?itemId=/content/journal/jgv/10.1099/jgv.0.002095&mimeType=html&fmt=ahah

References

  1. Bächi T, Howe C. Morphogenesis and ultrastructure of respiratory syncytial virus. J Virol 1973; 12:1173–1180 [View Article]
     [Google Scholar]
  2. Roberts SR, Lichtenstein D, Ball LA, Wertz GW. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 1994; 68:4538–4546 [View Article] [PubMed]
     [Google Scholar]
  3. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015a; 7:309ra162 [View Article] [PubMed]
     [Google Scholar]
  4. Verwey C, Ramocha L, Laubscher M, Baillie V, Nunes M et al. Pulmonary sequelae in 2-year-old children after hospitalisation for respiratory syncytial virus lower respiratory tract infection during infancy: an observational study. BMJ Open Respir Res 2023; 10:e001618 [View Article] [PubMed]
     [Google Scholar]
  5. UK Health Security Agency Respiratory syncytial virus (RSV): symptoms, transmission, prevention, treatment. n.d https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-symptoms-transmission-prevention-treatment/respiratory-syncytial-virus-rsv-symptoms-transmission-prevention-treatment accessed 12 November 2024
  6. Wang X, Li Y, Shi T, Bont LJ, Chu HY et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. The Lancet 2024; 403:1241–1253 [View Article]
     [Google Scholar]
  7. Linder KA, Malani PN. RSV infection in older adults. JAMA 2023; 330:1200 [View Article]
     [Google Scholar]
  8. Chadha M, Hirve S, Bancej C, Barr I, Baumeister E et al. Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. Influenza Resp Viruses 2020; 14:638–646 [View Article]
     [Google Scholar]
  9. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet 2022; 399:2047–2064 [View Article]
     [Google Scholar]
  10. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther 2023; 12:1137–1149 [View Article]
     [Google Scholar]
  11. Taylor S, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F et al. Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ Open 2016; 6:e009337 [View Article] [PubMed]
     [Google Scholar]
  12. Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis 2024; 37:129–136 [View Article] [PubMed]
     [Google Scholar]
  13. Allinson JP, Chaturvedi N, Wong A, Shah I, Donaldson GC et al. Early childhood lower respiratory tract infection and premature adult death from respiratory disease in Great Britain: a national birth cohort study. The Lancet 2023; 401:1183–1193 [View Article]
     [Google Scholar]
  14. Driscoll AJ, Arshad SH, Bont L, Brunwasser SM, Cherian T et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine 2020; 38:2435–2448 [View Article] [PubMed]
     [Google Scholar]
  15. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435–448 [View Article] [PubMed]
     [Google Scholar]
  16. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422–434 [View Article] [PubMed]
     [Google Scholar]
  17. Killikelly AM, Kanekiyo M, Graham BS. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep 2016; 6:34108 [View Article] [PubMed]
     [Google Scholar]
  18. Graham BS. Immunological goals for respiratory syncytial virus vaccine development. Curr Opin Immunol 2019; 59:57–64 [View Article] [PubMed]
     [Google Scholar]
  19. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592–598 [View Article] [PubMed]
     [Google Scholar]
  20. Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines. Pathogens 2023; 12:1259 [View Article] [PubMed]
     [Google Scholar]
  21. Tang Y-D, Li Y, Cai X-H, Yin X. Viral live-attenuated vaccines (LAVs): past and future directions. Adv Sci 2025; 12:e2407241 [View Article] [PubMed]
     [Google Scholar]
  22. Karron RA, Luongo C, Mateo JS, Wanionek K, Collins PL et al. Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-seronegative children. J Infect Dis 2020; 222:82–91 [View Article] [PubMed]
     [Google Scholar]
  23. Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ et al. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children. J Infect Dis 2022; 226:2069–2078 [View Article]
     [Google Scholar]
  24. Ogonczyk-Makowska D, Brun P, Vacher C, Chupin C, Droillard C et al. Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice. NPJ Vaccines 2024; 9:111 [View Article] [PubMed]
     [Google Scholar]
  25. Bayer L, Fertey J, Ulbert S, Grunwald T. Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice. Vaccine 2018; 36:1561–1569 [View Article] [PubMed]
     [Google Scholar]
  26. Eberlein V, Rosencrantz S, Finkensieper J, Besecke JK, Mansuroglu Y et al. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias. Front Immunol 2024; 15:1382318 [View Article] [PubMed]
     [Google Scholar]
  27. Chen F, Park H-R, Ji HJ, Kwon Y, Kim M-K et al. Gamma irradiation-inactivated respiratory syncytial virus vaccine provides protection but exacerbates pulmonary inflammation by switching from prefusion to postfusion F protein. Microbiol Spectr 2023; 11:e0135823 [View Article] [PubMed]
     [Google Scholar]
  28. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12:905–907 [View Article] [PubMed]
     [Google Scholar]
  29. Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol 2023; 97:2499–2574 [View Article] [PubMed]
     [Google Scholar]
  30. Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front Microbiol 2022; 12: [View Article]
     [Google Scholar]
  31. Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020; 383:426–439 [View Article] [PubMed]
     [Google Scholar]
  32. Trinité B, Durr E, Pons-Grífols A, O’Donnell G, Aguilar-Gurrieri C et al. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice. Vaccine 2024; 42:3474–3485 [View Article] [PubMed]
     [Google Scholar]
  33. Kim MJ, Chu KB, Lee SH, Mao J, Eom GD et al. Assessing the protection elicited by virus-like particles expressing the RSV pre-fusion F and tandem repeated G proteins against RSV rA2 line19F infection in mice. Respir Res 2024; 25: [View Article]
     [Google Scholar]
  34. Lee SH, Chu KB, Kim MJ, Mao J, Eom GD et al. Virus-like particle vaccine expressing the respiratory syncytial virus pre-fusion and G proteins confers protection against RSV challenge infection. Pharmaceutics 2023; 15:782 [View Article]
     [Google Scholar]
  35. Zhang L, Zhao G, Cheng X, Wang S, Wang J et al. A Phase 2 random, double-blind, placebo-controlled study of the safety and immunogenicity of A recombinant G protein-based respiratory syncytial virus vaccine in healthy older adults. MedRxiv 2023 [View Article]
     [Google Scholar]
  36. Gidwani SV, Brahmbhatt D, Zomback A, Bassie M, Martinez J et al. Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages. Nat Commun 2024; 15:2202 [View Article] [PubMed]
     [Google Scholar]
  37. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol 2020; 145:1309–1321 [View Article] [PubMed]
     [Google Scholar]
  38. Stephens LM, Varga SM. Nanoparticle vaccines against respiratory syncytial virus. Future Virol 2020; 15:763–778 [View Article] [PubMed]
     [Google Scholar]
  39. Menon I, Kang SM, D’Souza M. Nanoparticle formulation of the fusion protein virus like particles of respiratory syncytial virus stimulates enhanced in vitro antigen presentation and autophagy. Int J Pharm 2022; 623:121919 [View Article] [PubMed]
     [Google Scholar]
  40. Bavarian Nordic Bavarian Nordic provides update on RSV vaccine program; 2023 https://www.bavarian-nordic.com/investor/news/news.aspx?news=6808
  41. Comeaux CA, Bart S, Bastian AR, Klyashtornyy V, De Paepe E et al. Safety, immunogenicity, and regimen selection of Ad26.RSV.preF–based vaccine combinations: a randomized, double-blind, placebo-controlled, phase 1/2a Study. J Infect Dis 2024; 229:19–29 [View Article]
     [Google Scholar]
  42. Spearman P, Jin H, Knopp K, Xiao P, Gingerich MC et al. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study. Sci Adv 2023; 9:eadj7611 [View Article] [PubMed]
     [Google Scholar]
  43. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165–175 [View Article] [PubMed]
     [Google Scholar]
  44. Wu N, Zhang J, Shen Y, Zhang X, Zhou J et al. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections. Mol Ther 2024; 32:1033–1047 [View Article] [PubMed]
     [Google Scholar]
  45. U.S. Food and Drug Administration FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. n.d https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine accessed 14 November 2024
  46. European Medicines Agency First RSV vaccine to protect infants up to 6 months of age and older adults; 2023 https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults accessed 14 November 2024
  47. Hause AM, Moro PL, Baggs J, Zhang B, Marquez P et al. Early Safety findings among persons aged ≥60 years who received a respiratory syncytial virus vaccine — United States, May 3, 2023–April 14, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:489–494 [View Article]
     [Google Scholar]
  48. Papapetropoulos A, Topouzis S, Alexander SPH, Cortese-Krott M, Kendall DA et al. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. Br J Pharmacol 2024; 181:1553–1575 [View Article] [PubMed]
     [Google Scholar]
  49. Moderna Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R); 2024 https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-European-Commission-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx accessed 14 November 2024
  50. Papi A, Ison MG, Langley JM, Lee D-G, Leroux-Roels I et al. Respiratory syncytial virus prefusion f protein vaccine in older adults. N Engl J Med 2023; 388:595–608 [View Article] [PubMed]
     [Google Scholar]
  51. Saito M, Kono H, Morii H, Uedaira H, Tahirov TH et al. Cavity-filling mutations enhance protein stability by lowering the free energy of native state. J Phys Chem B 2000; 104:3705–3711 [View Article]
     [Google Scholar]
  52. Stewart-Jones GBE, Thomas PV, Chen M, Druz A, Joyce MG et al. A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. PLoS One 2015; 10:e0128779 [View Article] [PubMed]
     [Google Scholar]
  53. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465–1477 [View Article]
     [Google Scholar]
  54. Che Y, Gribenko AV, Song X, Handke LD, Efferen KS et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci Transl Med 2023; 15:eade6422 [View Article] [PubMed]
     [Google Scholar]
  55. Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P. All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?. Vaccines 2024; 12:97 [View Article] [PubMed]
     [Google Scholar]
  56. Espeseth AS, Cejas PJ, Citron MP, Wang D, DiStefano DJ et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines 2020; 5:16 [View Article] [PubMed]
     [Google Scholar]
  57. Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother 2021; 17:1248–1261 [View Article] [PubMed]
     [Google Scholar]
  58. Joyce MG, Zhang B, Ou L, Chen M, Chuang G-Y et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol 2016; 23:811–820 [View Article] [PubMed]
     [Google Scholar]
  59. Nussbaum J, Cao X, Railkar RA, Sachs JR, Spellman DS et al. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine 2023; 41:6488–6501 [View Article] [PubMed]
     [Google Scholar]
  60. Shaw CA, Stewart-Jones GBE, Jorquera P, Narayanan E, Elbashir S et al. Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus. In Review 2024 [View Article]
     [Google Scholar]
  61. Zhang L, More KR, Ojha A, Jackson CB, Quinlan BD et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 2023; 8:156 [View Article] [PubMed]
     [Google Scholar]
  62. Suryadevara M. Passive Immunization strategies to prevent severe respiratory syncytial virus infection among newborns and young infants. J Pediatric Infect Dis Soc 2024; 13:S110–S114 [View Article] [PubMed]
     [Google Scholar]
  63. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021; 11:CD013757 [View Article] [PubMed]
     [Google Scholar]
  64. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388:1451–1464 [View Article] [PubMed]
     [Google Scholar]
  65. Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med 2022; 386:1615–1626 [View Article] [PubMed]
     [Google Scholar]
  66. Boytchev H. Maternal RSV vaccine: Further analysis is urged on preterm births. BMJ 2023; 381:1021 [View Article]
     [Google Scholar]
  67. GSK GSK provides further update on phase III RSV maternal vaccine candidate programme; 2022 https://www.gsk.com/en-gb/media/press-releases/gsk-provides-further-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme accessed 14 November 2024
  68. Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W et al. RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. N Engl J Med 2024; 390:1009–1021 [View Article] [PubMed]
     [Google Scholar]
  69. Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR et al. Use of the pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States. MMWR Morbidity and Mortality Weekly Report 2023; 72:1115–1122 [View Article]
     [Google Scholar]
  70. Son M, Riley LE, Staniczenko AP, Cron J, Yen S et al. Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes. JAMA Netw Open 2024; 7:e2419268 [View Article] [PubMed]
     [Google Scholar]
  71. Leroux-Roels I, Bruhwyler J, Stergiou L, Sumeray M, Joye J et al. Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine. Vaccines 2023; 11:367 [View Article] [PubMed]
     [Google Scholar]
  72. Ruckwardt TJ, Morabito KM, Phung E, Crank MC, Costner PJ et al. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir Med 2021; 9:1111–1120 [View Article] [PubMed]
     [Google Scholar]
  73. Moderna Moderna Receives U.S FDA Approval for RSV Vaccine mRESVIA(R); 2024 https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx accessed 14 November 2024
  74. Chirkova T, Rosas-Salazar C, Gebretsadik T, Jadhao SJ, Chappell JD et al. Effect of infant RSV infection on memory T cell responses at Age 2-3 Years. Front Immunol 2022; 13:826666 [View Article] [PubMed]
     [Google Scholar]
  75. Lambert L, Sagfors AM, Openshaw PJM, Culley FJ. Immunity to RSV in early-life. Front Immunol 2014; 5:112039
     [Google Scholar]
  76. Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev 2017; 30:481–502 [View Article] [PubMed]
     [Google Scholar]
  77. Recto CG, Fourati S, Khellaf M, Pawlotsky J-M, De Prost N et al. Respiratory syncytial virus vs influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population. J Infect Dis 2024; 230:1130–1138 [View Article]
     [Google Scholar]
  78. Alfano F, Bigoni T, Caggiano FP, Papi A. Respiratory syncytial virus infection in older adults: an update. Drugs Aging 2024; 41:487–505 [View Article] [PubMed]
     [Google Scholar]
  79. Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) Candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis 2023; 227:761–772 [View Article] [PubMed]
     [Google Scholar]
  80. Ison MG, Papi A, Athan E, Feldman RG, Langley JM et al. Efficacy and safety of respiratory syncytial Virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clinc Infect Dis 2024; 78:1732–1744 [View Article]
     [Google Scholar]
  81. Pfizer U.S. FDA Approves Pfizer’S RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease; 2024 https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-rsv-vaccine-abrysvor-adults-aged-18
  82. Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM et al. A Randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis 2022; 225:1357–1366 [View Article] [PubMed]
     [Google Scholar]
  83. Falsey AR, Walsh EE, Scott DA, Gurtman A, Zareba A et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis 2022; 225:2056–2066 [View Article] [PubMed]
     [Google Scholar]
  84. Melgar M, Britton A, Roper LE, Talbot HK, Long SS et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023. Am J Transplant 2023; 23:1631–1640 [View Article] [PubMed]
     [Google Scholar]
  85. Shaw CA, Essink B, Harper C, Mithani R, Kapoor A et al. Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. J Infect Dis 2024; 230:e647–e656 [View Article] [PubMed]
     [Google Scholar]
  86. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G et al. Efficacy and safety of an mRNA-based RSV PreF Vaccine in Older Adults. N Engl J Med 2023; 389:2233–2244 [View Article]
     [Google Scholar]
  87. Editors from The Medical Letter A new RSV vaccine (mResvia) for adults ≥60 years old. Med Lett Drugs Ther 2024; 66:166–168 [View Article]
     [Google Scholar]
  88. Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. The Lancet 2024; 404:1547–1559 [View Article]
     [Google Scholar]
  89. Surie D, Self WH, Zhu Y, Yuengling KA, Johnson CA et al. RSV vaccine effectiveness against hospitalization among US Adults 60 years and older. JAMA 2024; 332:1105–1107 [View Article] [PubMed]
     [Google Scholar]
  90. Pfizer Pfizer announces positive top-line results from phase 3 study of ABRYSVO® in adults aged 18 to 59 at increased risk for RSV disease; 2024 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-1 accessed 14 November 2024
  91. Davis M, Towner W, DeHaan EN, Jiang Q, Li W et al. P-596. Immunobridging demonstrating effectiveness of the bivalent respiratory syncytial virus (RSV) Prefusion F Subunit vaccine in adults 18-59 years of age at high risk of severe RSV disease in a phase 3 trial: the C3671023 MONeT study results. Open Forum Infect Dis 2025; 12: [View Article]
     [Google Scholar]
  92. GSK New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease; 2024 https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-a-broader-group-of-adults-at-increased-risk-for-rsv-disease/ accessed 14 November 2024
  93. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215–1224 [View Article] [PubMed]
     [Google Scholar]
  94. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of Pediatrics 2003; 143:532–540 [View Article]
     [Google Scholar]
  95. Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med 2023; 29:1172–1179 [View Article] [PubMed]
     [Google Scholar]
  96. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383:415–425 [View Article] [PubMed]
     [Google Scholar]
  97. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386:837–846 [View Article] [PubMed]
     [Google Scholar]
  98. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM et al. Nirsevimab for Prevention of hospitalizations due to RSV in infants. N Engl J Med 2023; 389:2425–2435 [View Article] [PubMed]
     [Google Scholar]
  99. Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med 2022; 386:892–894 [View Article] [PubMed]
     [Google Scholar]
  100. Ares-Gómez S, Mallah N, Santiago-Pérez M-I, Pardo-Seco J, Pérez-Martínez O et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis 2024; 24:817–828 [View Article] [PubMed]
     [Google Scholar]
  101. Department of Health and Social Care Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June 2023; 2023 https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023
  102. MSD MSD’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants; 2024 https://www.msd.com/news/msds-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv-preventative-monoclonal-antibody-significantly-reduced-incidence-of-rsv-disease-and-hospitalization-in-health/ accessed 14 November 2024
  103. Simões EAF, Forleo-Neto E, Geba GP, Kamal M, Yang F et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis 2021; 73:e4400–e4408 [View Article] [PubMed]
     [Google Scholar]
  104. Levi M, Watson S, Anderson AB, Taylor D, White JT et al. 383. pharmacokinetics and safety in healthy adults of RSM01, a novel RSV monoclonal antibody, and population PK modeling to support pediatric development. Open Forum Infect Dis 2023; 10:ofad500 [View Article]
     [Google Scholar]
  105. Aljabr W, Touzelet O, Pollakis G, Wu W, Munday DC et al. Investigating the Influence of ribavirin on human respiratory syncytial virus RNA synthesis by using a high-resolution transcriptome sequencing approach. J Virol 2016; 90:4876–4888 [View Article] [PubMed]
     [Google Scholar]
  106. NICE Ribavirin. n.d https://bnf.nice.org.uk/drugs/ribavirin/#indications-and-dose accessed 14 November 2024
  107. Briggs GG, Freeman RK, Towers CV, Forinash AB. Briggs Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk Lippincott Williams & Wilkins; 2021
     [Google Scholar]
  108. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007; 1:CD000181 [View Article] [PubMed]
     [Google Scholar]
  109. Huang L-M, Schibler A, Huang Y-C, Tai A, Chi H et al. Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial. Influenza Other Respir Viruses 2023; 17:e13176 [View Article] [PubMed]
     [Google Scholar]
  110. ArkBio Ark Biopharmaceutical Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection; 2022 https://www.arkbiosciences.com/80/84
  111. Zhao S, Shang Y, Yin Y, Zou Y, Xu Y et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection. N Engl J Med 2024; 391:1096–1107 [View Article]
     [Google Scholar]
  112. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010; 36:646–654 [View Article] [PubMed]
     [Google Scholar]
  113. Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep 2016; 6:28698 [View Article] [PubMed]
     [Google Scholar]
  114. Menzel M, Akbarshahi H, Tufvesson E, Persson C, Bjermer L et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget 2017; 8:31601–31611 [View Article]
     [Google Scholar]
  115. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res 2010; 11:90 [View Article]
     [Google Scholar]
  116. Beigelman A, Goss CW, Wang J, Srinivasan M, Boomer J et al. Azithromycin therapy in infants hospitalized for respiratory syncytial virus bronchiolitis. Ann Allergy Asthma Immunol 2024; 132:623–629 [View Article]
     [Google Scholar]
  117. Ukkonen RM, Renko M, Kuitunen I. Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis. Pediatr Res 2024; 95:1441–1447 [View Article] [PubMed]
     [Google Scholar]
  118. Nikiforow S, Horwitz M, McCarty JM, Abbas A, Coghill JM et al. ALVR106, an Off-the-shelf, multivirus-specific T-cell therapy, for the treatment of respiratory viral infections: results from a phase 1, first-in-human, dose-ranging trial. Blood 2023; 142:6889 [View Article]
     [Google Scholar]
  119. De C, Pickles RJ, Yao W, Liao B, Boone A et al. Human T cells efficiently control RSV infection. JCI Insight 2023; 8:11 [View Article] [PubMed]
     [Google Scholar]
  120. Bavarian Nordic Bavarian Nordic provides update on RSV vaccine program; 2023 https://www.bavarian-nordic.com/investor/news/news.aspx?news=6808 accessed 14 November 2024
  121. Stuart ASV, Virta M, Williams K, Seppa I, Hartvickson R et al. Phase 1/2a safety and immunogenicity of an adenovirus 26 vector respiratory syncytial virus (RSV) vaccine encoding prefusion F in adults 18-50 years and RSV-seropositive children 12-24 Months. J Infect Dis 2022; 227:71–82 [View Article] [PubMed]
     [Google Scholar]
  122. AstraZeneca AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data; 2023 https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html accessed 14 November 2024
  123. Díez-Domingo J, Sáez-Llorens X, Rodriguez-Weber MA, Epalza C, Chatterjee A et al. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12-23 months of age. J Infect Dis 2023; 227:1293–1302 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.002095
Loading
Recent advances in the prevention and treatment of respiratory syncytial virus disease
J. Gen. Virol. 106, 002095 (2025); https://doi.org/10.1099/jgv.0.002095
/content/journal/jgv/10.1099/jgv.0.002095
/content/journal/jgv/10.1099/jgv.0.002095
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error